VJOncology is committed to improving our service to you

ESMO 2017 | How can durvalumab be used in NSCLC?

VJOncology is committed to improving our service to you

Sanjay Popat

Sanjay Popat, BSc MBBS FRCP PhD, from the Royal Marsden Hospital, London, UK, discusses highlights from the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The PACIFIC study (NCT02125461) was a large, randomised Phase III trial investigating the use of durvalumab in non-small cell lung cancer patients who had completed concomitant chemo-radiotherapy. This trial had a combined endpoint of progression free and overall survival, with durvalumab being significantly superior to placebo. Durvalumab could be considered as consolidation therapy for patients completing thoracic chemoradiotherapy.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter